First-in-human trial initiations reveal four KRAS assets.

A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.

But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.

But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.

BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.

What similarly acting projects are still unpartnered?

Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.

After a conference lacking the wow factor, biotech winners and losers emerge.

Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.